Arno Advances Cancer Pipeline with $12.7M Private Placement
By Catherine Shaffer
Wednesday, November 28, 2012
Arno Therapeutics Inc., of Flemington, N.J., closed a $12.7 million private placement of convertible debentures to support research and development of oncology drugs onapristone and AR-42.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.